Cargando…

New agents in the Treatment of Myeloma Bone Disease

Patients with multiple myeloma develop a devastating bone disease driven by the uncoupling of bone remodelling, excess osteoclastic bone resorption and diminished osteoblastic bone formation. The bone phenotype is typified by focal osteolytic lesions leading to pathological fractures, hypercalcaemia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ring, Elizabeth S., Lawson, Michelle A., Snowden, John A., Jolley, Ingrid, Chantry, Andrew D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805798/ https://www.ncbi.nlm.nih.gov/pubmed/29098361 http://dx.doi.org/10.1007/s00223-017-0351-7

Ejemplares similares

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
por: Paton‐Hough, Julia, et al.
Publicado: (2018)

NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease
por: Lawson, Michelle A., et al.
Publicado: (2015)

Myeloma Bone Disease: The Osteoblast in the Spotlight
por: Andrews, Rebecca E., et al.
Publicado: (2021)

The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma
por: Stewart, Georgia, et al.
Publicado: (2021)

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo
por: Lath, Darren L., et al.
Publicado: (2018)

Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo
por: Vitovski, Srdjan, et al.
Publicado: (2012)

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
por: Teramachi, Jumpei, et al.
Publicado: (2023)

The role of bone‐modifying agents in myeloma bone disease
por: Lu, Huifang, et al.
Publicado: (2021)

HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models
por: Tazzyman, Simon, et al.
Publicado: (2023)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Bone Pain in Multiple Myeloma (BPMM)—A Protocol for a Prospective, Longitudinal, Observational Study
por: Diaz-delCastillo, Marta, et al.
Publicado: (2021)

Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Myeloma Bone Disease
por: Sanderson, Ralph D, et al.
Publicado: (2009)

What Can Patient Narratives Reveal to Us About the Experience of a Diagnosis of Myeloma? A Qualitative Scoping Review
por: Rubins, Zoë, et al.
Publicado: (2022)

Differential Pain‐Related Behaviors and Bone Disease in Immunocompetent Mouse Models of Myeloma
por: Diaz‐delCastillo, Marta, et al.
Publicado: (2019)

Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma
por: Buckle, Clive Henry, et al.
Publicado: (2012)

Pathogenesis and treatment of multiple myeloma bone disease
por: Hiasa, Masahiro, et al.
Publicado: (2021)

Pathogenesis and Treatment of Myeloma-Related Bone Disease
por: Gau, Yuh-Ching, et al.
Publicado: (2022)

The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma
por: Crawford, Lisa J., et al.
Publicado: (2020)

Use of bone‐modifying agents and clinical outcomes in older adults with multiple myeloma
por: Olszewski, Adam J., et al.
Publicado: (2019)

New investigational drugs with single-agent activity in multiple myeloma
por: Rajan, A M, et al.
Publicado: (2016)

Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience
por: Kass-Iliyya, Lewis, et al.
Publicado: (2020)

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
por: Vallet, Sonia, et al.
Publicado: (2018)

The role of the bone microenvironment in regulating myeloma residual disease and treatment
por: Dadzie, Terry G., et al.
Publicado: (2022)

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche
por: Müller, Louise M E, et al.
Publicado: (2021)

Kinase inhibitors as potential agents in the treatment of multiple myeloma
por: Abramson, Hanley N.
Publicado: (2016)

Animal Models of Multiple Myeloma Bone Disease
por: Mehdi, Syed Hassan, et al.
Publicado: (2021)

Myeloma bone disease: Pathophysiology and management
por: Silbermann, Rebecca, et al.
Publicado: (2013)

Multiple Myeloma Associated Bone Disease
por: Rasch, Stine, et al.
Publicado: (2020)

Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement
por: Tosi, Patrizia
Publicado: (2013)

Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease
por: Charvátová, Sandra, et al.
Publicado: (2023)

Innovative Agents in Multiple Myeloma
por: Faiman, Beth, et al.
Publicado: (2014)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

An Improved Animal Model of Multiple Myeloma Bone Disease
por: Mehdi, Syed Hassan, et al.
Publicado: (2021)

Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions
por: Raus, Svjetlana, et al.
Publicado: (2011)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

New agents for bone metastasis
por: Hortobagyi, GN
Publicado: (2005)

Bone Disease in Multiple Myeloma: Pathophysiology and Management
por: Hameed, Abdul, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0rdmqpeknhepdfls570kv4fmq1